Report Overview

The US ADHD (Attention-Deficit Hyperactivity Disorder) market size stood at USD 4.61 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity and the structural difference in the mind. Symptoms of the Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period and varies according to the type of causing factor and according to the age group of the person. The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or ADHD, low-stress tolerance level, mood swings and many more. Further, based on symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive, and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient mental and behaviour condition. Various treatment options are pharmacological treatment, educational interventions & other behavioural therapies and EEG biofeedback therapies, physicians could reduce the disorder symptoms and its effects on the individual health.



Market Drivers

The US attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs and mounting occurrence of ADHD. Key trends and developments of this market includes progressing drugs under pipeline, high demand for dual therapy and rising preference for EEG biofeedback therapy. However, there are some factors which can hinder growth of the market including Medical complications of existing drug therapies, high domination of generic pharmaceutical market and strict government protocols.